Discover KRAZATI® (adagrasib), an oral treatment for adult patients with previously treated KRAS G12C-positive NSCLC. Learn about safety, testing, and support options.

Find out how KRAZATI® (adagrasib), an oral, FDA approved treatment, works for adult patients with NSCLC and whose tumor has an abnormal KRAS G12C gene.

Learn about taking KRAZATI® (adagrasib) for adult patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Follow recommended dosages and manage side effects.

Access support for KRAZATI® (adagrasib) NSCLC patients. Get assistance with coverage and care. Download additional resources, including the Patient Brochure and FAQs.

KRAZATI is a prescription medicine used in adults alone to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment.

What is KRAZATI? MORE KRAZATI is a prescription medicine used in adults alone to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment.

What is KRAZATI? MORE KRAZATI is a prescription medicine used in adults alone to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment.

KRAZATI ® (adagrasib) Not an actual patient. KRAZATI is a 600-mg, twice-daily, chemo-free, targeted oral medication that is taken with cetuximab, an infusion therapy.

visit www.KRAZATI.com/c KRAZATI + cetuximab combination therapy is a chemo-free, targeted treatment option for your KRAS G12C-positive advanced CRC. What is KRAZATI? KRAZATI is a prescription medicine used in adults: • in combination with a medicine called cetuximab to treat colon or rectal cancer (CRC)